reports
Aspira Women’s Health Announces Appointment of Dr. Sandra Milligan as ...
Aspira Women’s Health Announces Appointment of Dr. Sandra Milligan as Interim CEO CEO Nicole Sandford will step down for personal reasons and will remain as a consultant to ensure a seamless transition AUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matter. Aspira...
Aspira Women’s Health Successfully Reaches the First Milestone of the ...
Aspira Women’s Health Successfully Reaches the First Milestone of the ARPA-H $10 Million Award The Company received the first $2 million from the ARPA-H Sprint for Women’s Health Award AUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the successful completion of the first development milestone of its (ARPA-H) award. As a result, Aspira has received a $2 million cash payment under the terms of the related a...
Aspira Women’s Health Reports Selected Third Quarter 2024 Financial Re...
Aspira Women’s Health Reports Selected Third Quarter 2024 Financial Results Q3 2024 OvaSuiteSM revenue of $2.3 million and volume of 6,001 units Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second quarter of 2024 Full year 2024 cash guidance reconfirmed as $13.0-$14.5 million Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic...
Aspira Women’s Health Expands Co-Marketing and Distribution Collaborat...
Aspira Women’s Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch® BioReference team is now able to provide the entire OvaSuite portfolio to healthcare providers in New York and New Jersey AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the expansion of its co-marketing and distribution collaboration with BioReference Health, LLC (“BioReference”), a wholly-own...
Aspira Women’s Health to Announce Third Quarter Earnings Results and H...
Aspira Women’s Health to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 14, 2024 Management to Announce Earnings Results and hold a call at 8:30 am ET AUSTIN, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three and nine months ended September 30, 2024, on Thursday, November 14, 2024. Management w...
Aspira Women’s Health Issues Letter to Shareholders and Announces Virt...
Aspira Women’s Health Issues Letter to Shareholders and Announces Virtual Research & Development Day on October 29, 2024 Event to feature presentations from Dr. Kevin Elias, Dr. Richard Gersh, Dr. Sandra Milligan, and Dr. Todd Pappas on the Company’s development pipeline AUSTIN, Texas, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, has issued a letter to Company shareholders and announced it will host a virtual Research & Development D...
Aspira Women’s Health Selected to Receive $10 Million Award from ARPA-...
Aspira Women’s Health Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health Aspira aims to develop a multi-marker miRNA blood test to aid in the detection of endometriosis AUSTIN, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has been selected by the (ARPA-H) as an of the to address critical unmet challenges in women’s health, champion transformative innovations, and tackle health c...
Aspira Women’s Health Receives Approval from New York State Department...
Aspira Women’s Health Receives Approval from New York State Department of Health for OvaWatch® New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation (CLEP) approval allows for OvaWatch® to be marketed in New York State AUSTIN, Texas, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has received approval from the New York State Department of Health’s (NYSDOH) Clinical Laboratory Evaluation Pro...
Aspira Women’s Health Announces Publication of Data Demonstrating Perf...
Aspira Women’s Health Announces Publication of Data Demonstrating Performance of its In-Development Blood Test for the Assessment of Malignancy Risk in Patients with an Adnexal Mass The addition of miRNA and metadata to Aspira’s existing protein assay shows promising improvements in both sensitivity and specificity for early-stage ovarian cancer in women with an adnexal mass AUSTIN, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools...
Aspira Women’s Health to Present at the H.C. Wainwright 26th Annual Gl...
Aspira Women’s Health to Present at the H.C. Wainwright 26th Annual Global Investment Conference AUSTIN, Texas, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, CEO of Aspira Women’s Health will present at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY. The presentation will be available on demand on Mo...
Aspira Women’s Health Selected as a Spoke for the Investor Catalyst Hu...
Aspira Women’s Health Selected as a Spoke for the Investor Catalyst Hub “Spoke” designation acknowledges Aspira’s position as an innovator in women’s health, and provides new opportunities for funding, thought leadership and networking with other healthcare industry leaders AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it was selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPA...
Aspira Women’s Health Partners with Dorsata to Create New Clinical Wor...
Aspira Women’s Health Partners with Dorsata to Create New Clinical Workflow Tool for Adnexal Masses The innovative new tool will be made available for integration into Electronic Medical Records at over 300 clinical sites serving 2,500 clinical users AUSTIN, Texas, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today signed a definitive agreement with Dorsata, a healthcare software company, to create a protocol workflow tool for the cl...
Aspira Women’s Health Reports Second Quarter 2024 Financial Results
Aspira Women’s Health Reports Second Quarter 2024 Financial Results Q2 2024 OvaSuiteSM revenue of $2.4 million and volume of 6,471 units Q2 2024 cash utilization decreased by 16% compared to Q1 2024 Full year 2024 cash guidance decreased to $13-$14.5 million Conference Call and Webcast scheduled for today at 4:30 pm ET AUSTIN, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results ...
Aspira Women’s Health’s Announces a Poster Presentation at the 27th An...
Aspira Women’s Health’s Announces a Poster Presentation at the 27th Annual National Association of Nurse Practitioners in Women’s Health (NPWH) Women’s Healthcare Conference AUSTIN, Texas, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced a poster presentation at the 27th Annual National Association of Nurse Practitioner’s in Women’s Health (NPWH) Woman’s Healthcare Conference being held on September 25-28, 2024, in Chicago,...
Aspira Women’s Health Announces Poster Presentation at the Menopause S...
Aspira Women’s Health Announces Poster Presentation at the Menopause Society’s 2024 Annual Meeting Presentation to highlight data demonstrating OvaWatch’s performance in assessing ovarian cancer risk in pre- and post-menopausal women AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced a poster presentation at the upcoming Annual Meeting of The Menopause Society being held on September 10-14, 2024 in Chicago, I...
Aspira Women’s Health to Announce Second Quarter Earnings Results and ...
Aspira Women’s Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 12 AUSTIN, Texas, July 31, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended June 30, 2024, on Monday, August 12, 2024. Management will also host a conference call at 4:30 p.m. Eastern Time to discuss financial results and provide ...
Aspira Women’s Health Appoints Mr. John Ragard to its Board of Directo...
Aspira Women’s Health Appoints Mr. John Ragard to its Board of Directors Mr. Ragard further strengthens the Board bringing more than 46 years of significant public equity investment and Wall Street experience AUSTIN, Texas, July 29, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mr. John Ragard to its Board of Directors. Mr. Ragard is an accomplished executive with extensive experience successfully managing se...
Aspira Women’s Health Announces Preliminary Second Quarter 2024 OvaSui...
Aspira Women’s Health Announces Preliminary Second Quarter 2024 OvaSuite Product Volume and Highlights Preliminary OvaWatch® volume during Q2 2024 grew 24% over the prior quarter to 1,307 units Preliminary OvaSuiteSM volume during Q2 2024 grew 11% over the prior quarter to 6,471 units AUSTIN, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced preliminary second quarter 2024 OvaSuite product volume a...
Aspira Women’s Health Announces Closing of $1.9 Million Private Placem...
Aspira Women’s Health Announces Closing of $1.9 Million Private Placement Equity Financing AUSTIN, Texas, July 09, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has closed its previously announced private placement for the issuance and sale of shares of the Company’s common stock and accompanying warrants to purchase an equal number of shares for gross proceeds of approximately $1.9 million. Aspira has t...
Aspira Women’s Health Announces $1.935 Million Private Placement Equit...
Aspira Women’s Health Announces $1.935 Million Private Placement Equity Financing AUSTIN, Texas, July 01, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has entered into a securities purchase agreement dated June 30, 2024 with certain existing accredited shareholders and Company insiders to issue and sell an aggregate of 1,264,739 shares of its common stock (“Common Stock”) and warrants to purchase an equal num...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.